Publications by authors named "L Zenari"
Introduction: Combination therapy with both basal insulin (BI) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) is an effective treatment in patients with uncontrolled type 2 diabetes mellitus (T2DM). The recent development and release of a fixed-ratio combination of slow-release insulin degludec and the GLP-1RA liraglutide (IDegLira) represents an improvement to this therapy. We have conducted a real-world evidence study in Italian patients with T2DM to evaluate whether the encouraging clinical trial results obtained with IDegLira, which became available in Italy in January 2018, can be confirmed in Italian clinical practice.
View Article and Find Full Text PDFArticle Synopsis
- - This study evaluated the long-term effectiveness of liraglutide for type 2 diabetes over 5 years, focusing on its impact on metabolic parameters and cardiovascular risk.
- - In the study involving 103 patients, significant improvements were observed in HbA1c, fasting plasma glucose, body weight, blood pressure, and lipid profiles, with more patients achieving target HbA1c levels.
- - The findings indicated that while liraglutide reduced the risk of coronary heart disease, it did not significantly affect stroke risk, suggesting that its cardiovascular benefits are specific to heart-related outcomes.
Background: Type 2 diabetes may alter cardiac structure and function. Many patients with type 2 diabetes have diastolic dysfunction with preserved ejection fraction (EF). Recently, this latter measure was criticised.
View Article and Find Full Text PDFBackground: Type 2 diabetes is strongly associated with the occurrence of cardiovascular diseases, especially heart failure. Some studies have suggested that subclinical systolic dysfunction as assessed by tissue Doppler imaging (TDI) is already present in uncomplicated diabetic patients with normal left ventricular ejection fraction (LVEF). Considering the importance of this aspect, the aim of this cross-sectional study was to examine the relationship between glycated hemoglobin and mean s' wave velocity (a reliable measure of early LV systolic dysfunction) in a cohort of type 2 diabetic outpatients with preserved LVEF and without ischemic heart disease.
View Article and Find Full Text PDFAims: It is known that type 2 diabetic patients are at high risk of atrial fibrillation (AF). However, the early echocardiographic determinants of AF vulnerability in this patient population remain poorly known.
Methods: We followed-up for 2years a sample of 180 consecutive outpatients with type 2 diabetes, who were free from AF and ischemic heart disease at baseline.